And Faiez Zannad.

William B. White, M.D., Christopher P. Cannon, M.D., Simon R. Heller, M.D., Steven E. Nissen, M.D., Richard M. Bergenstal, M.D., George L. Bakris, M.D., Alfonso T. Perez, M.D., Penny R. Fleck, M.B.A., Cyrus R. Mehta, Ph.D., Stuart Kupfer, M.D., Craig Wilson, Ph.D., William C. Cushman, M.D., and Faiez Zannad, M.D., Ph.D. For the EXAMINE Investigators: Alogliptin after Acute Coronary Syndrome in Individuals with Type 2 Diabetes Type 2 diabetes is associated with both macrovascular and microvascular complications.1 The risk of cardiovascular disease is two to four situations as high in people with diabetes as in people without diabetes.1,2 Improved glycemic control may reduce the risk of many microvascular problems of diabetes,3 but studies have not shown a good effect of glycemic control in lowering macrovascular events in sufferers with type 2 diabetes.4,5 Concerns relating to adverse cardiovascular outcomes with antidiabetic agents6,7 prompted the meals and Drug Administration to issue guidance in December 2008 that included particular requirements for cardiovascular safety assessment before and after the authorization of new antidiabetic therapies.8 Regulatory agencies in other countries have adopted similar plans.Vulnerable plaque or high risk plaque that is most likely to rupture and cause thrombosis historically by no means wasn’t revealed showed up in most of the angiography outcomes. That is whenMore recently, Optical Coherence Tomography , which usedwas mainly utilized in ophthalmology, made its entry in to the interventional cardiology. Helpful in assessing the pathophysiology of thrombosis-prone plaque in – vivo, OCT provides ten instances higher resolutions compared to the Intra Vascular Ultra audio . The intra-coronary imaging demonstrates plaque rupture, plaque erosion, intracoronary thrombosis, thin cap fibroatheroma and calcified nodule. Detailed and clear microscopic visualization of the culprit lesion morphology assists the physicians to create a better risk stratification for ACS.